Company intelligence / Profile preview

Angitec

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Angitec is a biotechnology company focused on the development of novel therapeutics for cardiovascular diseases, specifically targeting vascular regeneration and repair. A spin-out from King's College London, the company's research centers on the role of epigenetic regulators in blood vessel formation and maintenance. Its primary focus is on small molecule modulators of Histone deacetylase 7 (HDAC7) to treat conditions such as heart failure and atherosclerosis. By stimulating endogenous repair mechanisms, Angitec aims to provide transformative treatments for patients with chronic vascular damage.

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

King's College London

Beyond the preview

Go deeper on Angitec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angitec.

Explore the full profile